Clinical experience with interferon alfa-2a for exudative age-related macular degeneration.
AUTOR(ES)
Kirkpatrick, J N
RESUMO
There has been recent interest in the use of systemic interferon alfa-2a treatment for choroidal neovascular membranes (CNV). Here a pilot study is reported in which 10 patients with exudative age-related macular degeneration (ARMD) have been treated with a course of interferon injections. Of nine eyes with CNV there has been clinical and angiographic improvement in one eye and maintenance of visual acuity at pretreatment levels in three eyes (mean follow up period 7.6 months). Clinical appearance in five eyes was unchanged but these eyes still had active CNV. Two eyes with pigment epithelial detachment showed no clinical or angiographic change after interferon therapy although visual acuity in one eye had improved. Interferon alfa-2a may have a role to play in the treatment of ARMD as an adjunct to laser photocoagulation.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=504651Documentos Relacionados
- Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b.
- Postoperative abnormalities of the choriocapillaris in exudative age-related macular degeneration.
- The prospects for new treatments in age-related macular degeneration.
- Symmetry of disciform scars in bilateral age-related macular degeneration.
- Red blood cell antioxidant enzymes in age-related macular degeneration.
